A COMPARATIVE STUDY OF THE HEPATOTROPIC PROPERTIES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

K. Shchokina, G. Belik, D. Semeniv, V. Ulanova

1 National University of Pharmacy of Ukraine of the Ministry of Health of Ukraine
2 Ivanо-Frankivsk National Medical University

Aims. To study the effect of different generations of NSAIDs on the functional state of the liver of the experimental animals.

Materials and methods. Diclofenac sodium, piroxicam, indomethacin, meloxicam and celecoxib were selected for the comparative study. Changes in the functional state of the liver of intact rats during subchronic administration of the drugs selected, as well as their impact on the course of the model hepatitis were determined. The state of the liver was determined by the following indicators: the mass coefficient of the liver; the content of total protein, urea, cholesterol in the blood serum; the level of TBA-active products, diene conjugates; reduced glutathione, catalase and glycogen in the liver homogenate.

Results and discussion. It was found that diclofenac, piroxicam, indomethacin in the doses of ED_{50} by the antieuxudative activity when used for 14 days adversely affected the liver of intact animals, as well as worsened the course of the model hepatitis, i.e. had a pronounced hepatotoxic effect. Meloxicam and celecoxib did not show a pronounced adverse effect in the carbon tetrachloride hepatitis, but contributed to the deterioration of the functional state of the liver of intact rats, i.e. had a moderate hepatotoxic effect.

Conclusions. By the level of hepatotoxicity the drugs studied can be arranged as follows: diclofenac > indomethacin > piroxicam > meloxicam > celecoxib.

Key words: hepatotoxicity; diclofenac sodium; indomethacin; piroxicam; meloxicam; celecoxib

Topicality. Recently, more and more works on the hepatotoxicity of NSAIDs have appeared in the literature. Presumably, all NSAIDs have hepatotoxicity, but the degree of adverse effects on the liver in different drugs is variable.

Aim. To study the effect of different generations of NSAIDs on the functional state of the liver of the experimental animals.

Materials and methods. Diclofenac sodium, piroxicam, indomethacin, meloxicam and celecoxib were selected for the comparative study. Changes in the functional state of the liver of intact rats during subchronic administration of the drugs selected, as well as their impact on the course of the model hepatitis were determined. The state of the liver was determined by the following indicators: the mass coefficient of the liver; the activity of alanine aminotransferase, alkaline phosphatase, the content of total protein, urea, cholesterol in the blood serum, the level of TBA-active products, diene conjugates; reduced glutathione, catalase and glycogen in the liver homogenate.

Results and discussion. It was found that diclofenac, piroxicam, indomethacin in the doses of ED_{50} by the antieuxudative activity when used for 14 days adversely affected the liver of intact animals, as well as worsened the course of the model hepatitis, i.e. had a pronounced hepatotoxic effect. Meloxicam and celecoxib did not show a pronounced adverse effect in the carbon tetrachloride hepatitis, but contributed to the deterioration of the functional state of the liver of intact rats, i.e. had a moderate hepatotoxic effect.

Conclusions. By the level of hepatotoxicity the drugs studied can be arranged as follows: diclofenac > indomethacin > piroxicam > meloxicam > celecoxib.

Key words: hepatotoxicity; diclofenac sodium; indomethacin; piroxicam; meloxicam; celecoxib

K. G. Щокіна, Г. В. Бєлік, Д. В. Семенів, В. А. Уланова

1 Національний фармацевтичний університет Міністерства охорони здоров’я України
2 Івано-Франківський національний медичний університет

Порівняльне дослідження гепатотропних властивостей нестероїдних противізапальних препаратів

Актуальність. Останнім часом у літературі з’являється все більше робіт, присвячених питанням гепатотоксичності НПЗП. Імовірно, всі НПЗП характеризуються гепатотоксичністю, однак ступінь негативного впливу на печінку в різних препаратів варіабельний.

Метою пропонованої роботи стало порівняльне вивчення впливу препаратів різних поколінь НПЗП на функціональний стан печінки експериментальних тварин.

Матеріали та методи. Для порівняння дослідження було обрано диклофенак натрію, піроксикам, індометацин, мелоксикам та целекоксиб. Визначали зміни функціонального стану печінки інтактних тварин за такими показниками: масовий коефіцієнт печінки; активність аланінамінотрансферази, лужної фосфатази, активність аспартатамінотрансферази, активність аланинамінотрансферази, активність аспартатамінотрансферази; активність глутатіону, каталази та глікогену в гомогенаті печінки.

Результати та їх обговорення. З’ясовано, що диклофенак, піроксикам, індометацин у дозах ED_{50} за антиексудативною активністю застосування протягом 14-ти днів негативно впливають на стан печінки інтактних тварин, а також погіршують перебіг модельного гепатиту, тобто проявляють виражену гепатотоксичну дію. Мелоксикам і целекоксиб не виявляли вираженої негативної дії у разі тетрахлорметанового гепатиту, але сприяли погіршенню функціонального стану печінки інтактних тварин, тобто чинять помірну гепатотоксичну дію.

Висновки. За рівнем гепатотоксичності порівняні препарати можна розташувати так: диклофенак > індометацин > піроксикам > мелоксикам > целекоксиб.

Ключові слова: гепатотоксичність, диклофенак натрію; індометацин; піроксикам; мелоксикам; целекоксиб

Е. Г. Щекіна, Г. В. Бєлік, Д. В. Семенів, В. А. Уланова

1 Національний фармацевтичний університет Міністерства здравоохорони України
2 Івано-Франківський національний медичний університет

Справжнє інтенсивне вивчення гепатотропних властивостей нестероїдних противізапальних препаратів

Актуальність. Відповідно до наукових досліджень, препарати з гепатотоксичністю та гепатомінералізуючою дією можуть зменшувати ліпідний спектр в тканинах печінки, знижуючи гепатометаболічне стresse, стимулюючи регенерацію тканин

Метою пропонованої роботи стало порівняльне вивчення впливу препаратів різних поколінь НПЗП на функціональний стан печінки експериментальних тварин.

Матеріали та методи. Для порівняння дослідження було обрано диклофенак натрію, піроксикам, індометацин, мелоксикам та целекоксиб. Визначали зміни функціонального стану печінки інтактних тварин за такими показниками: масовий коефіцієнт печінки; активність аланинамінотрансферази, активність аспартатамінотрансферази, активність аланинамінотрансферази, активність аспартатамінотрансферази, активність глутатіону, каталази та глікогену в гомогенаті печінки.

Результати та їх обговорення. З’ясовано, що диклофенак, піроксикам, індометацин у дозах ED_{50} за антиексудативною активністю застосування протягом 14-ти днів негативно впливають на стан печінки інтактних тварин, а також погіршують перебіг модельного гепатиту, тобто проявляють виражену гепатотоксичну дію. Мелоксикам і целекоксиб не виявляли вираженої негативної дії у разі тетрахлорметанового гепатиту, але сприяли погіршенню функціонального стану печінки інтактних тварин, тобто чинять помірну гепатотоксичну дію.

Висновки. За рівнем гепатотоксичності порівняні препарати можна розташувати так: диклофенак > індометацин > піроксикам > мелоксикам > целекоксиб.

Ключові слова: гепатотоксичність, диклофенак натрію; індометацин; піроксикам; мелоксикам; целекоксиб
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most popular groups of drugs. According to the WHO, about 20% of the world's population regularly uses drugs of this group [1]. At the same time, NSAID-associated side effects are the subject of large-scale scientific and practical discussions and the object of numerous experimental and clinical studies. It is known that one of the main complications of this group of drugs is the development of NSAID gastropathies [2, 3]. The side effects of NSAIDs also include liver and kidney dysfunctions, hematological reactions, etc. [4, 5]. Recently in the literature there are more and more works devoted to the issues of hepatotoxicity of NSAIDs [6-8]. Experts come to the conclusion that there is a relationship between the frequency of liver damage and the use of NSAIDs; however, there is no consensus on this issue at the moment. It was previously believed that the main link in the pathogenesis of hepatotoxicity was inhibition of the prostaglandin synthesis. However, recently this hypothesis has been revised [9, 10]. In the pathogenesis of the NSAID-associated liver damage, there is blockade of the enzyme systems of the Krebs cycle and the uncoupling of oxidative phosphorylation (similar to the Reye's syndrome) in the mitochondria of hepatocytes, blockade of phosphodiesterase IV, impaired excretion of bile due to the formation of bulky complexes of NSAID metabolites with bile acids, enterohepatic treatment, as well as immunological disorders [11].

Probably all modern NSAIDs have hepatotoxicity; however, the degree of the negative effect on the liver is very variable. Therefore, the aim of our work was a comparative study of the effect of different generations of NSAIDs on the functional state of the liver of the experimental animals.

MATERIALS AND METHODS

Five widely used NSAIDs of different generations were selected for the comparative study, namely diclofenac sodium, piroxicam, indomethacin, meloxicam, and celecoxib.

To determine the effect of the drugs selected on the functional state of the liver of intact rats, the latter were administered intragastrically in the dose of ED\text{50} by the antixudative activity for 14 days: diclofenac sodium in the dose of 8 mg/kg, piroxicam – 2 mg/kg, indomethacin – 5 mg/kg, meloxicam – 1 mg/kg, celecoxib – 7 mg/kg [1, 14]. On Day 15, animals were removed from the experiment, their blood was collected, and the liver was removed.

The condition of the liver was determined by the following indicators: the mass coefficient of liver (LMC), alanine aminotransferase (ALT), alkaline phosphatase (ALPh), total protein (TP), urea, cholesterol (ChS) in the serum; the level of TBA-active products (TBA-AP), diene conjugates (DC), reduced glutathione (RG), catalase and glycogen in the liver homogenate.

LMC was calculated by the formula:

$$\text{LMC} = \left( \frac{M_{\text{liver}}}{M_{\text{animal}}} \right) \times 100\%.$$

The ALT activity was determined by the Reitman-Freund method, AL – by the Bessel-Lowry-Brock method, the level of TP – by the biuret reaction, ChS – by the Ilko method (using standard biochemical kits), and the urea content – by the Menshikov method [15]. TBA-AP, DC was determined by the reaction with 2-thiobarbituric acid spectrophotometrically using the method of I. D. Steel, T. G. Garishvili, and the RG content – by the method of Beutler E. D. et al. The level of glycogen in the liver was determined by the method of Kemp and Kitz, catalase – by the method of MO Korolyuk and co-authors [16].

INTRODUCTION

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most popular groups of drugs. According to the WHO, about 20% of the world's population regularly uses drugs of this group [1]. At the same time, NSAID-associated side effects are the subject of large-scale scientific and practical discussions and the object of numerous experimental and clinical studies. It is known that one of the main complications of this group of drugs is the development of NSAID gastropathies [2, 3]. The side effects of NSAIDs also include liver and kidney dysfunctions, hematological reactions, etc. [4, 5]. Recently in the literature there are more and more works devoted to the issues of hepatotoxicity of NSAIDs [6-8]. Experts come to the conclusion that there is a relationship between the frequency of liver damage and the use of NSAIDs; however, there is no consensus on this issue at the moment. It was previously believed that the main link in the pathogenesis of hepatotoxicity was inhibition of the prostaglandin synthesis. However, recently this hypothesis has been revised [9, 10]. In the pathogenesis of the NSAID-associated liver damage, there is blockade of the enzyme systems of the Krebs cycle and the uncoupling of oxidative phosphorylation (similar to the Reye’s syndrome) in the mitochondria of hepatocytes, blockade of phosphodiesterase IV, impaired excretion of bile due to the formation of bulky complexes of NSAID metabolites with bile acids, enterohepatic treatment, as well as immunological disorders [11].

Despite the fact that the relative risk of liver damage due to the use of NSAIDs is relatively low (8-27 cases per 100 thousand patients per year), the consequences of the resulting NSAID-induced liver damage are often the most serious [12]. The problem of the hepatotoxic effect of some NSAIDs is so acute that in a number of countries these drugs are prohibited. For example, nimesulide is currently banned for use in Spain, Finland, Israel, India, Sri Lanka. In the USA, UK, Canada and Australia, the drug was not approved for registration [13].
RESULTS AND DISCUSSION

The results of the comparative study of the effect of anti-inflammatory drugs on the functional state of the liver of intact rats are presented in Tab. 1.

According to the data obtained, diclofenac showed the greatest negative impact on the functional state of the liver of healthy animals with subchronic administration (within 2 weeks). The level of cholesterol increased by 2 times compared to the intact control group. A decrease in the content of TP in the blood serum by 1.6 times indicated a decrease in the protein-synthetic function of the liver. A probable increase ALPh by 1.6 times proved the presence of cholestasis and inflammation in the liver [17]. The increase in the level of RG in the liver homogenate by one and a half time was a consequence of the deterioration of the functional state of the antioxidant system of the body (AOS) of the experimental animals. Other liver parameters in the diclofenac group did not differ significantly from those in the intact control group.

The use of piroxicam also led to the deterioration of the functional state of the liver of intact animals. There was a significant increase in the content of ChS in the serum of animals (1.8 times higher than in the intact control group). The level of SB decreased by 1.4 times, i.e. the protein-synthetic function of the liver was suppressed. The ALPh activity increased in 1.5 times. A significant increase in the level of TBA-AP (by 1.3 times), and the tendency to increase the content of DC in the liver homogenate indicated an increase in the intensity of the processes of lipids peroxide oxidation (LPO) in the liver of animals. Compared to diclofenac, piroxicam caused a more pronounced increase in the activity of LPO processes (the content of TBA-AP in the liver homogenate increased in 1.3 times more than in the group of animals treated with diclofenac).

Under the effect of indomethacin there was a tendency to increase LMC, increase the level of ALPh by 1.4 times, reduce the content of SB (1.3 times), and increase the content of ChS in the serum (1.7 times compared to the group of intact animals). In the liver homogenate, the level of TBA-AP increased by 1.4 times compared to the same indicator in the intact control group. There was a tendency to increase the content of DC. Thus, indomethacin worsened the liver, promoted the activation of sex processes. Compared to diclofenac, indomethacin was less effective in reducing TP and increasing ChS in the serum, but the level of TBK-AP under the action of indomethacin increased in 1.3 times more than on the background of diclofenac.

Meloxicam and celecoxib also contributed to some extent to the deterioration of the functional state of the liver.

Table 1

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Intact control (n = 10)</th>
<th>Indomethacin (n = 10)</th>
<th>Diclofenac (n = 10)</th>
<th>Piroxicam (n = 10)</th>
<th>Meloxicam (n = 10)</th>
<th>Celecoxib (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMC, %</td>
<td>3.3 ± 0.1</td>
<td>3.5 ± 0.2</td>
<td>3.7 ± 0.1*</td>
<td>3.6 ± 0.2</td>
<td>3.5 ± 0.3</td>
<td>2.8 ± 0.1**</td>
</tr>
<tr>
<td>Blood serum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT, mmol/hour x l</td>
<td>0.5 ± 0.08</td>
<td>0.5 ± 0.06</td>
<td>0.6 ± 0.02</td>
<td>0.5 ± 0.04</td>
<td>0.5 ± 0.05</td>
<td>0.4 ± 0.05**</td>
</tr>
<tr>
<td>ALPh, mccat/l</td>
<td>0.7 ± 0.10</td>
<td>0.9 ± 0.08*</td>
<td>1.1 ± 0.06*</td>
<td>1.0 ± 0.05*</td>
<td>0.8 ± 0.06**</td>
<td>0.8 ± 0.04**</td>
</tr>
<tr>
<td>Urea, mmol/l</td>
<td>4.7 ± 0.2</td>
<td>4.9 ± 0.2</td>
<td>4.8 ± 0.1</td>
<td>4.5 ± 0.2</td>
<td>4.3 ± 0.3</td>
<td>4.3 ± 0.3</td>
</tr>
<tr>
<td>TP, g/l</td>
<td>60.2 ± 2.1</td>
<td>46.1 ± 1.4**</td>
<td>38.6 ± 1.0*</td>
<td>42.4 ± 2.2*</td>
<td>54.7 ± 2.1**</td>
<td>58.8 ± 1.6</td>
</tr>
<tr>
<td>ChS, mmol/l</td>
<td>1.2 ± 0.1</td>
<td>2.0 ± 0.3/**</td>
<td>2.8 ± 0.1*</td>
<td>2.2 ± 0.4*</td>
<td>2.1 ± 0.2/**</td>
<td>2.7 ± 0.2*</td>
</tr>
<tr>
<td>Liver tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DC, mmol/g</td>
<td>5.3 ± 0.6</td>
<td>6.4 ± 0.8</td>
<td>4.7 ± 0.6</td>
<td>6.4 ± 0.5</td>
<td>5.3 ± 0.4</td>
<td>4.9 ± 0.7</td>
</tr>
<tr>
<td>TBA-AP, mmol/g</td>
<td>103.1 ± 10.4</td>
<td>141.8 ± 8.1/**</td>
<td>112.2 ± 6.3</td>
<td>138.6 ± 7.7/**</td>
<td>108.2 ± 6.9</td>
<td>105.7 ± 4.9</td>
</tr>
<tr>
<td>Catalase, mmol/g</td>
<td>0.3 ± 0.03</td>
<td>0.2 ± 0.03</td>
<td>0.2 ± 0.05</td>
<td>0.2 ± 0.04</td>
<td>0.3 ± 0.07</td>
<td>0.3 ± 0.03</td>
</tr>
<tr>
<td>Glycogen, mg/g</td>
<td>25.9 ± 4.2</td>
<td>20.3 ± 4.9</td>
<td>19.4 ± 3.9</td>
<td>22.1 ± 2.5</td>
<td>17.1 ± 3.3</td>
<td>28.2 ± 2.9</td>
</tr>
</tbody>
</table>

Notes: * - deviation of the indicator is significant for the group of the intact control, p < 0.05; ** – deviation is significant for the diclofenac group, p < 0.05.
the liver of healthy animals. Under the effect of meloxicam the level of ALPh increased (by 2 times), indicating the presence of cholestasis and inflammation in the liver. Meloxicam and celecoxib contributed to an increase in cholesterol (by 2.3 times) compared to the similar indicators in the intact control group.

Therefore, diclofenac, piroxicam, indomethacin when used for 14 days in intact animals showed a pronounced hepatotoxic effect. Meloxicam and celecoxib in the similar experimental conditions also contributed to the deterioration of the functional state of the liver. By reducing the hepatotoxic effect the drugs were arranged as follows: diclofenac > piroxicam > indomethacin > meloxicam ≥ celecoxib.

We continued the comparative study of the hepatotoxic effect of the drugs selected on the model of acute fatty liver disease — tetrachloromethane hepatitis in rats. The condition of the liver was determined by indicators similar to those in the previous experiment, as well as by the survival rate of animals. The results of this study are presented in Tab. 2.

In the control pathology group, the development of fatty degeneration of the liver was observed; it was accompanied by an increase in the mass coefficient of the liver by 1.8 times compared to the intact control group, indicating severe intoxication and the development of inflammation in the liver tissue under the effect of carbon tetrachloride [1, 9]. By the end of the experiment, half of the animals died (survival was 50 %). The level of ChS in the blood increased in 1.8 times. The increase in the serum ChS is a compensatory reaction in the intensification of LPO processes since in hypercholesterolemia ChS is more easily integrated into cell membranes and stabilizes them [18].

The increased ALPh activity (by 2.6 times) suggested the presence of inflammation and cholestasis in the liver. A decrease in the protein content of liver in the blood serum of animals was by 1.3 times.

A sharp increase in the ALT activity (1.7 times compared to the intact control group) indicated an increase in cytolysis in the liver, which correlated with an increase in LPO processes. The decrease in the level of RG (by 1.7 times) and catalase (by 2.4 times) in the homogenate of the organ was a consequence of the suppression of AOS in animals. The antitoxic function of the liver was also suppressed, as evidenced the increased level of urea in the serum of control animals. The content of glycogen in the liver decreased in 2 times, indicating a decrease in the synthetic function of the liver.

The drugs affected the severity of the pathological process in the liver to varying degrees. The use of indomethacin did not reduce the hepatotoxic effect of carbon tetrachloride, on the contrary, a significant increase in the content of TBA-AP (by 1.2 times), DC (by 1.1 times) decreased the level of RG in the liver homogenate (by 1.2 times) compared to the similar indicators in animals of the control pathology group. However, the introduction of indomethacin contributed to a significant reduction in the ALT activity in the liver homogenate (by 1.2 times) and the level of cholesterol in the blood (by 3.6 times). The survival of the animals increased by one and a half time compared to the control pathology group and was 75 %.

Diclofenac did not also reduce the hepatotoxic effect of carbon tetrachloride. There was a significant increase in relation to the control pathology, the content of ChS in the serum increased by 1.3 times. The introduction of

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Intact control (n = 6)</th>
<th>Control pathology (n = 12)</th>
<th>Indomethacin (n = 10)</th>
<th>Diclofenac (n = 10)</th>
<th>Piroxicam (n = 10)</th>
<th>Meloxicam (n = 10)</th>
<th>Celecoxib (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival, %</td>
<td>100</td>
<td>50</td>
<td>75</td>
<td>62.5</td>
<td>75</td>
<td>87.5</td>
<td>75</td>
</tr>
<tr>
<td>LMC, mmol/g</td>
<td>3.1 ± 0.2</td>
<td>5.5 ± 0.2*</td>
<td>5.2 ± 0.1*</td>
<td>6.0 ± 0.1*/**</td>
<td>5.3 ± 0.4*</td>
<td>4.8 ± 0.3*</td>
<td>5.3 ± 0.4*</td>
</tr>
<tr>
<td>ALT, mmol/hour x l</td>
<td>0.5 ± 0.1</td>
<td>1.6 ± 0.2*</td>
<td>1.1 ± 0.1*</td>
<td>1.1 ± 0.1*</td>
<td>1.2 ± 0.2*</td>
<td>1.0 ± 0.1*/**</td>
<td>1.7 ± 0.2*</td>
</tr>
<tr>
<td>ALPh, mmol/l</td>
<td>1.3 ± 0.2</td>
<td>3.2 ± 0.6*</td>
<td>3.1 ± 0.6*</td>
<td>3.6 ± 0.9*</td>
<td>3.4 ± 0.5*</td>
<td>3.0 ± 0.3**</td>
<td>2.9 ± 0.3**</td>
</tr>
<tr>
<td>Urea, mmol/l</td>
<td>4.7 ± 0.5</td>
<td>7.9 ± 0.7*</td>
<td>8.1 ± 0.4*</td>
<td>5.3 ± 0.6**</td>
<td>9.4 ± 0.8*</td>
<td>8.0 ± 0.6*</td>
<td>8.2 ± 0.7*</td>
</tr>
<tr>
<td>TP, g/l</td>
<td>60.2 ± 2.1</td>
<td>46.7 ± 3.6*</td>
<td>49.3 ± 4.1*</td>
<td>42.9 ± 5.3</td>
<td>46.1 ± 4.4*</td>
<td>56.6 ± 4.2</td>
<td>58.4 ± 5.8</td>
</tr>
<tr>
<td>ChA, mmol/l</td>
<td>2.2 ± 0.3</td>
<td>3.9 ± 0.2*</td>
<td>2.1 ± 0.4**</td>
<td>5.0 ± 0.3*/**</td>
<td>2.0 ± 0.1**</td>
<td>2.9 ± 0.3**</td>
<td>3.2 ± 0.2*</td>
</tr>
<tr>
<td>DC, mmol/g</td>
<td>5.3 ± 0.6</td>
<td>7.7 ± 0.4*</td>
<td>8.7 ± 0.3*/**</td>
<td>7.2 ± 0.4*</td>
<td>7.9 ± 0.5*</td>
<td>7.5 ± 0.4*</td>
<td>7.3 ± 0.5*</td>
</tr>
<tr>
<td>TBA-AP, mmol/g</td>
<td>109.1 ± 15.4</td>
<td>178.3 ± 8.8*</td>
<td>209.1 ± 10.3*/**</td>
<td>153.7 ± 11.1*</td>
<td>166.3 ± 12.3*</td>
<td>152.9 ± 13.4</td>
<td>155.7 ± 12.8*</td>
</tr>
<tr>
<td>RG, mmol/g</td>
<td>0.4 ± 0.02</td>
<td>0.2 ± 0.05*</td>
<td>0.2 ± 0.05*</td>
<td>0.1 ± 0.04*</td>
<td>0.2 ± 0.03*</td>
<td>0.2 ± 0.02*</td>
<td>0.2 ± 0.04*</td>
</tr>
<tr>
<td>Catalase, mmol/g</td>
<td>0.3 ± 0.03</td>
<td>0.1 ± 0.02*</td>
<td>0.1 ± 0.03*</td>
<td>0.2 ± 0.04*</td>
<td>0.1 ± 0.05*</td>
<td>0.3 ± 0.05**</td>
<td>0.3 ± 0.03**</td>
</tr>
<tr>
<td>Glycogen, mg/g</td>
<td>22.3 ± 4.2</td>
<td>11.3 ± 1.9*</td>
<td>16.9 ± 3.4</td>
<td>9.6 ± 2.1*</td>
<td>12.4 ± 3.9*</td>
<td>14.2 ± 2.9</td>
<td>10.2 ± 1.3*</td>
</tr>
</tbody>
</table>

Notes: * — deviation of the indicator is significant for the group of the intact control, p < 0.05; ** — deviation of the indicator is significant for the group of the control pathology, p < 0.05.
the drug helped to reduce the content of TBK-AP, but the level of RG decreased by 1.7 times. The survival of the animals was 62.5% (less than in the group of animals receiving indomethacin, but more than in the group of the control pathology).

In the group of animals treated with piroxicam, there was a tendency to increase LMC compared to the control pathology group. There were significantly increased area levels in the serum of animals, indicating a decrease in the anionic (ammonia-detoxifying) function of the liver. However, the introduction of piroxicam significantly reduced the activity of ALT (in 1.2 times), i.e. there was a tendency to reduce cytolytic processes in the liver. The survival of rats was 75%.

Against the background of the introduction of meloxicam, there was a decrease in MCP (decreased in 1.2 times compared to the control pathology group), the marker of ALT cytolysis decreased in 1.3 times, the serum cholesterol decreased in 1.35 times. A significant increase in TP in the blood serum by 1.2 times indicated a tendency to reduce cytolytic processes in the liver. The survival was 75%.

The use of celecoxib contributed to the reduction of inflammatory processes and cholestasis in the liver (the level of ALPh in the serum decreased by 1.3 times, the total protein content increased by 1.3 times). Under the effect of the drug the level of LPO decreased (the content of TBA-AP in the homogenate of the organ decreased by 1.2 times). The survival was 75%.

Thus, during the experiment it was found that diclofenac, piroxicam, indomethacin in the doses of ED50 by the antiexudative activity when used for 14 days adversely affected the liver of intact animals, as well as worsened the course of the model hepatitis, i.e. had a pronounced hepatotoxic effect. Meloxicam and celecoxib did not show a pronounced adverse effect in the carbon tetrachloride hepatitis, but contributed to the deterioration of the functional state of the liver of intact rats, i.e. had a moderate hepatotoxic effect.

**CONCLUSIONS**

By the level of hepatotoxicity the drugs studied can be arranged as follows: diclofenac > indomethacin > piroxicam > meloxicam > celecoxib.

**Conflict of interests:** authors have no conflict of interests to declare.

**REFERENCES**


